Here's Why Becton Dickinson (BDX) is a Strong Value Stock

Medical technology firm Becton Dickinson (BDX) is identified as a strong value stock, boasting a Zacks Rank #2 (Buy) and a 'B' Value Style Score, supported by an attractive forward P/E of 13.01. The company's fiscal 2025 earnings outlook has strengthened, with nine analysts raising estimates in the past 60 days, increasing the Zacks Consensus Estimate to $14.34 per share and reflecting an average earnings surprise of 6.5%.

Analysis

Becton Dickinson (BDX) has been identified as a compelling value opportunity, underpinned by a Zacks Rank of #2 (Buy) and a 'B' grade for both its Value and composite VGM Style Scores. The company's valuation appears attractive, highlighted by a forward P/E ratio of 13.01. This positive view is further supported by strengthening analyst sentiment for its fiscal 2025 outlook; nine analysts have revised their earnings estimates upward in the last 60 days, lifting the Zacks Consensus Estimate by $0.17 to $14.34 per share. Reinforcing this optimistic forecast is the company's historical performance, which includes an average positive earnings surprise of 6.5%, suggesting a consistent ability to exceed market expectations. The analysis is primarily driven by the momentum in earnings estimate revisions, which is the core of the proprietary rating model discussed.

Key Decisions for Investors

• Investors with a value-oriented strategy should consider BDX for inclusion on a shortlist, given its combination of a #2 (Buy) rating, a forward P/E of 13.01, and recent positive earnings estimate revisions.
• It is crucial to monitor the trend of analyst earnings revisions for fiscal 2025, as this momentum is the central pillar of the bullish thesis presented in the report.
• While the signals are strongly positive, investors should note this analysis is based on a single firm's proprietary model and should be corroborated with broader due diligence before making capital allocation decisions.